Idexx Laboratories Announces Director Retirement and Board Changes

The latest announcement is out from Idexx Laboratories ( (IDXX) ).

Idexx Laboratories, Inc. announced that director M. Anne Szostak notified the company on February 13, 2026, of her intention to retire from its Board of Directors immediately following the 2026 Annual Meeting of Stockholders scheduled for May 12, 2026. The company emphasized that her decision does not stem from any disagreement over operations or policies, and the Board has adjusted its Class III size upon her retirement while maintaining overall Board size in light of the previously announced addition of Michael G. Erickson, PhD, as a Class II director after the meeting.

The most recent analyst rating on (IDXX) stock is a Hold with a $750.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.

Spark’s Take on IDXX Stock

According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.

The score is anchored by strong financial quality (premium margins, solid free cash flow, and improved balance sheet) and supportive 2026 guidance. Offsetting factors are weak current technical momentum and a high P/E that leaves less room for error, with corporate execution risk around the CEO transition as a secondary consideration.

To see Spark’s full report on IDXX stock, click here.

More about Idexx Laboratories

Idexx Laboratories, Inc. is a diagnostics and technology company serving the animal health and related markets. The company develops and provides veterinary diagnostic products, laboratory services, and software solutions for veterinarians, livestock and poultry producers, and other animal health stakeholders worldwide.

Average Trading Volume: 547,824

Technical Sentiment Signal: Buy

Current Market Cap: $51.8B

For detailed information about IDXX stock, go to TipRanks’ Stock Analysis page.